|
Age-related macular degeneration (AMD)
is the leading cause of blindness worldwide in people over the
age of 50. An estimated 12 million Americans suffer from AMD,
with 1.2 million seriously impaired.
Two major factors contribute to the devastating
effects of AMD currently: patients are often not diagnosed until
they begin experiencing significant vision loss and therapies
that are available today are directed solely toward the most severe
patients.
AMD-iPAC has been established through
a collaborative effort of the state of Ohio, corporate sponsors,
investors, and leading academic institutions in order to develop
and commercialize new technologies for early diagnosis and treatment
of Age-Related Macular Degeneration. Efforts will also result
in increased investment in the state of Ohio through corporate
funding and involvement and the likely creation of jobs in the
biotechnology sector.
Recognized as a leader in ocular disease management,
the Cole Eye Institute provides:
- A world-class facility with over 30,000 patient
visits each year
- High quality ground-breaking basic and translational
research
- Opinion-leading knowledge and expertise of
clinical staff
|
The
AMD Initiative for Prevention & Cure is supported by 
